Zai Lab’s (NASDAQ:ZLAB) lock-up period is set to end on Monday, March 19th. Zai Lab had issued 8,333,333 shares in its public offering on September 20th. The total size of the offering was $149,999,994 based on an initial share price of $18.00. Shares of the company owned by company insiders and major shareholders will be eligible for trade following the end of the lock-up period.
A number of research analysts have weighed in on the stock. BidaskClub raised shares of Zai Lab from a “sell” rating to a “hold” rating in a research note on Wednesday, January 31st. JPMorgan Chase & Co. raised shares of Zai Lab from a “neutral” rating to an “overweight” rating and set a $32.00 target price on the stock in a research note on Wednesday, February 14th.
Shares of Zai Lab (NASDAQ:ZLAB) opened at $21.63 on Wednesday. Zai Lab has a 1-year low of $19.80 and a 1-year high of $35.74.
ILLEGAL ACTIVITY WARNING: This piece of content was originally posted by Week Herald and is owned by of Week Herald. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece of content can be viewed at https://weekherald.com/2018/03/14/zai-lab-ltds-zlab-lock-up-period-will-end-on-march-19th.html.
About Zai Lab
Zai Lab Ltd, incorporated on March 28, 2017, is a biopharmaceutical company. The Company is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including in the fields of oncology, autoimmune and infectious diseases.
Receive News & Ratings for Zai Lab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zai Lab and related companies with MarketBeat.com's FREE daily email newsletter.